Medindia LOGIN REGISTER
Medindia

Is Eli Lilly's Drug the Future of Obesity Treatment?

by Colleen Fleiss on Jun 18 2023 9:16 PM
Listen to this article
0:00/0:00

Eli Lilly's Mounjaro may prove an alternative to bariatric surgery, stated clinical trial results.

Is Eli Lilly`s Drug the Future of Obesity Treatment?
Eli Lilly's Mounjaro (tirzepatide) medication has successfully completed the trial for treating obesity (1 Trusted Source
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

Go to source
).
Diabetes drug Mounjaro's (tirzepatide) has spiked Eli Lilly's market value and made it the most valuable //pharmaceutical company in the world, with a market cap of $420 billion, surpassing Johnson & Johnson.

As a result of Mounjaro, Eli Lilly will remain one of the most highly valued pharmaceutical companies, said the report by GlobalData, a leading data and analytics company.

Exploring the Potential of Eli Lilly's Drug for Obesity Treatment

"Lilly's blockbuster therapy to tackle the global obesity pandemic will undoubtedly gain widespread adoption by patients and providers." said Akash Patel, Pharma Analyst at GlobalData.

"Mounjaro's approval in 2022 for Type-2 diabetes has already led to many prescribers providing the therapy off-label to their patients to help them lose weight," he added.

Lilly reported FY2022 sales of approximately $500 million for Mounjaro for Type-2 diabetes in the US and EU, but this is expected to increase significantly in 2023 due to strong demand for the drug for both diabetes and obesity.

A decision from the US Food and Drug Administration, regarding the treatment of Mounjaro for obesity, is possible later this year with Lilly currently finalising an application for fast-track approval.

"Key opinion leaders (KOLs) have reported that they have not seen a drug with similar efficacy in terms of Weight loss and are highly keen to prescribe the therapy for patients with Type-2 diabetes and obesity, or those with obesity and high risk for Type-2 diabetes and other cardiorenal comorbidities," Patel said.

Advertisement
Reference:
  1. Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 - (https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-achieved-157-weight-loss-adults-obesity-or)

Source-IANS


Advertisement

Home

Consult

e-Book

Articles

News

Calculators

Drugs

Directories

Education